Coeptis Therapeutics Holdings, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$-3
Book Value Per Share
$3
Free Cash Flow Per Share
$-2
Cash Per Share
—
Revenue Per Share
$0
OCF Per Share
$-2
Return on Equity
-140.7%
Return on Assets
-95.1%
Return on Invested Capital
-119.5%
Debt to Equity
0.01
Current Ratio
4.16
Quick Ratio
4.16
Asset Turnover
0.11
R&D / Revenue
93.7%
SBC / Revenue
—
Invested Capital
$14M
OCF / Net Income
0.72
FCF / Net Income
0.72
Accruals Ratio (Sloan)
-20.5%
Net Debt
$-527K
Net Debt / EBITDA
0.04
Interest Coverage
-134.82
Cash Coverage
-88.93
Tangible Common Equity
$13M
TCE / Total Assets
81.7%
NOPAT
$-10M
Cash ROIC
-99.8%
WC / Revenue
409.5%
Reinvestment Rate
9.1%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
—
Book Value 5Y CAGR
192.9%
Stock Price (FY-end)
$14
Market Cap
$60M
P/S Ratio
44.27
P/B Ratio
4.45
P/TB Ratio
4.57
Enterprise Value
$60M
EV / Sales
43.89
FCF Yield
-14.3%
Shareholder Yield
-10.4%
R&D Yield
2.1%
Shares Variation (YoY)
120.0%
Beta (5Y)
0.54
Cost of Equity
7.2%
Cost of Debt (after tax)
51.0%
52W High
$19
52W Low
$3
Trailing Return 1Y
291.1%
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.